Wednesday, October 14, 2026

Capital Allocation

2 articles

$122 Billion OpenAI Round Signals Coming Infrastructure Spending Wave

OpenAI's $122 billion funding round is expected to trigger a capital reallocation into AI infrastructure within 6-12 months. Compute providers, data center operators, and networking firms are positioned to absorb the downstream spending. Market conditions favor the thesis: the S&P 500 is approaching record highs in a risk-on environment.

LM Salvado•Jun 4, 2026

Duke Energy's $103B Capex Plan Shows AI Power Demand Is Rewriting Utility Budgets

Duke Energy has committed to a $103B five-year capital expenditure program anchored by electricity supply agreements with major hyperscalers, with its CEO signaling the figure will increase. The plan includes next-generation nuclear power, reflecting hyperscaler demand for continuous baseload-grade electricity. AI infrastructure buildout has now grown large enough to structurally reshape utility capital allocation across the sector.

LM Salvado•Apr 27, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,375 source documents archived

Query this data → isubstrate.com